Extended (Every 12 Weeks or Longer) Dosing Interval With Intravitreal Aflibercept and Ranibizumab in Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of VIEW Trials
Titel:
Extended (Every 12 Weeks or Longer) Dosing Interval With Intravitreal Aflibercept and Ranibizumab in Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of VIEW Trials
Auteur:
Khurana, Rahul N. Rahimy, Ehsan Joseph, W. Anthony Saroj, Namrata Gibson, Andrea Vitti, Robert Berliner, Alyson J. Chu, Karen Cheng, YenChieh Boyer, David S.